Oruka Therapeutics, Inc.
ORKA
Rang in aandelen
#3292
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Aandeelprijs
$80.01
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$5.30B
Verandering (1 dag)
1.16%
Verandering (1 jaar)
200.21%
Land
US
Handel Oruka Therapeutics, Inc. (ORKA)
Categorie
Healthcare
Winst voor Oruka Therapeutics, Inc. (ORKA)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Oruka Therapeutics, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Oruka Therapeutics, Inc. van 2005 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2025 | $-105.43M | 25.93% |
| 2024 | $-83.72M | 1,468.16% |
| 2023 | $-5.34M | -46.21% |
| 2022 | $-9.93M | -48.63% |
| 2021 | $-19.32M | 98.24% |
| 2020 | $-9.75M | 72.54% |
| 2019 | $-5.65M | -29.07% |
| 2018 | $-7.96M | -57.07% |
| 2017 | $-18.55M | 12.81% |
| 2016 | $-16.44M | 43.68% |
| 2015 | $-11.45M | 18.12% |
| 2014 | $-9.69M | 39.63% |
| 2013 | $-6.94M | 60.63% |
| 2012 | $-4.32M | -19.46% |
| 2011 | $-5.36M | -36.29% |
| 2010 | $-8.42M | -26.26% |
| 2009 | $-11.42M | -41.23% |
| 2008 | $-19.43M | 57.96% |
| 2007 | $-12.30M | -90.74% |
| 2006 | $-132.78M | 85.41% |
| 2005 | $-71.61M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
